SCHEMBL6480431

SCHEMBL6480431

COC(=O)Cc1cccc(Nc2ncnc(Cl)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.54
CCNT1 O60563 4/20 0.43
CCNE1 P24864 4/20 0.43
CDK2 P24941 4/20 0.43
CDK9 P50750 4/20 0.43
SCN9A Q15858 6/20 0.42
CCNE2 O96020 2/20 0.42
CCNK O75909 1/20 0.42
CDK1 P06493 1/20 0.42
YES1 P07947 1/20 0.42
LYN P07948 1/20 0.42
FGR P09769 1/20 0.42
SRC P12931 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42
EPHA1 P21709 1/20 0.42
ABL2 P42684 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
IRAK1 P51617 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479037 0.85 AURKA (0.54) SYKCCNT1CCNE1CDK2CDK9
SCHEMBL6497316 0.85 SYK (0.53) SYKCCNT1CCNE1CDK2CDK9
SCHEMBL6492733 0.80 PIK3CA (0.50) SYKSCN9A
SCHEMBL6479606 0.79 ABL1 (0.57) SCN9ASRCMEN1KMT2AALDH1A1
SCHEMBL589118 0.79 CCNT1 (0.58) CCNT1CCNE1CDK2CDK9CCNE2
SCHEMBL13726637 0.79 TNNI3K (0.46) CCNT1CCNE1CDK2CDK9SCN9A
SCHEMBL13727475 0.78 CDK2 (0.48) CCNT1CCNE1CDK2CDK9SCN9A
SCHEMBL13727588 0.78 TNNI3K (0.47) CCNT1CCNE1CDK2CDK9SCN9A
SCHEMBL4547562 0.78 SYK (0.53) SYKMEN1KMT2AALDH1A1POLB
SCHEMBL14062184 0.78 NFKB1 (0.43) SYKCCNT1CCNE1CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881737-B2 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. (US) 2005-04-19 US disclosed
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS SYK 593/4885CCNT1 513/4885CCNE1 551/4885
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA SYK 1232/4885CCNT1 1697/4885CCNE1 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.